Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
We have reviewed all subsequent events and transactions that occurred after the date of our March 31, 2020 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.
Effective May 5, 2020, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd (“VFMCRP”) entered into an amendment (the “VFMCRP Amendment”) to the Development and License Agreement, originally entered into in May 2016 for the development and commercialization of Rayaldee worldwide, except for (i) the U.S., (ii) any country in Central America or South America (excluding Mexico), (iii) Russia, (iv) China, (v) Japan, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, and (x) Taiwan (the “VFMCRP Territory”). Under the terms of the VFMCRP Amendment, EirGen and VFMCRP have agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, EirGen is eligible to receive up to $20 million in Regulatory Milestones and $210 million in Sales Milestones tied to launch, pricing and sales of Rayaldee.